Pfizer and Compugen sign in silico drug discovery deal
This article was originally published in Scrip
Executive Summary
Compugen, an Israeli drug and diagnostic developer, has agreed to use its predictive discovery technology to unearth peptide candidates for three Pfizer drug targets.